Terms: = Leukemia AND SF3B1, ENSG00000115524, 23451, O75533, SF3b155, SAP155, PRPF10, PRP10
455 results:
1. Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape.
Karel D; Valburg C; Woddor N; Nava VE; Aggarwal A
Curr Oncol; 2024 Apr; 31(4):1971-1993. PubMed ID: 38668051
[TBL] [Abstract] [Full Text] [Related]
2. Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients.
Borsi E; Vigliotta I; Poletti A; Mazzocchetti G; Solli V; Zazzeroni L; Martello M; Armuzzi S; Taurisano B; Kanapari A; Pistis I; Zamagni E; Pantani L; Rocchi S; Mancuso K; Tacchetti P; Rizzello I; Rizzi S; Dan E; Sinigaglia B; Cavo M; Terragna C
Cells; 2024 Apr; 13(8):. PubMed ID: 38667272
[TBL] [Abstract] [Full Text] [Related]
3. Small-molecule α-lipoic acid targets ELK1 to balance human neutrophil and erythrocyte differentiation.
Zhang Y; Zhou Y; Li X; Pan X; Bai J; Chen Y; Lai Z; Chen Q; Ma F; Dong Y
Stem Cell Res Ther; 2024 Apr; 15(1):100. PubMed ID: 38589882
[TBL] [Abstract] [Full Text] [Related]
4. Differential prognostic values of the three AKT isoforms in acute myeloid leukemia.
Corre E; Soum C; Pfeifer R; Bessière C; Dailhau S; Marbœuf C; Meggetto F; Touriol C; Récher C; Bousquet M; Pyronnet S
Sci Rep; 2024 Mar; 14(1):7070. PubMed ID: 38528080
[TBL] [Abstract] [Full Text] [Related]
5.
Moison C; Gracias D; Schmitt J; Girard S; Spinella JF; Fortier S; Boivin I; Mendoza-Sanchez R; Thavonekham B; MacRae T; Mayotte N; Bonneil E; Wittman M; Carmichael J; Ruel R; Thibault P; Hébert J; Marinier A; Sauvageau G
Sci Adv; 2024 Mar; 10(12):eadl4018. PubMed ID: 38517966
[TBL] [Abstract] [Full Text] [Related]
6. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
Mata DA; Lee JK; Shanmugam V; Marcus CB; Schrock AB; Williams EA; Ritterhouse LL; Hickman RA; Janovitz T; Patel NR; Kroger BR; Ross JS; Mirza KM; Oxnard GR; Vergilio JA; Elvin JA; Benhamida JK; Decker B; Xu ML
Histopathology; 2024 Jun; 84(7):1224-1237. PubMed ID: 38422618
[TBL] [Abstract] [Full Text] [Related]
7. [The Correlation of Gene Mutation and Clinical Characteristics in Patients with Myelodysplastic Syndrome and Prognostic Analysis].
Zhang WW; Zhang YL; Ren CC; Wu TK; Liu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):176-183. PubMed ID: 38387918
[TBL] [Abstract] [Full Text] [Related]
8. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
Shimony S; Bewersdorf JP; Shallis RM; Liu Y; Schaefer EJ; Zeidan AM; Goldberg AD; Stein EM; Marcucci G; Lindsley RC; Chen EC; Ramos Perez J; Stein A; DeAngelo DJ; Neuberg DS; Stone RM; Ball B; Stahl M
Leukemia; 2024 Apr; 38(4):762-768. PubMed ID: 38378841
[TBL] [Abstract] [Full Text] [Related]
9. The clinical characteristics, gene mutations and outcomes of myelodysplastic syndromes with diabetes mellitus.
Xu F; Jin J; Guo J; Xu F; Chen J; Liu Q; Song L; Zhang Z; Zhou L; Su J; Xiao C; Zhang Y; Yan M; He Q; Wu D; Chang C; Li X; Wu L
J Cancer Res Clin Oncol; 2024 Feb; 150(2):71. PubMed ID: 38305890
[TBL] [Abstract] [Full Text] [Related]
10. Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.
van de Loosdrecht AA; Cremers EMP; Alhan C; Duetz C; In 't Hout FEM; Visser-Wisselaar HA; Chitu DA; Verbrugge A; Cunha SM; Ossenkoppele GJ; Janssen JJWM; Klein SK; Vellenga E; Huls GA; Muus P; Langemeijer SMC; de Greef GE; Te Boekhorst PAW; Raaijmakers MHG; van Marwijk Kooy M; Legdeur MC; Wegman JJ; Deenik W; de Weerdt O; van Maanen-Lamme TM; Jobse P; van Kampen RJW; Beeker A; Wijermans PW; Biemond BJ; Tanis BC; van Esser JWJ; Schaar CG; Noordzij-Nooteboom HS; Jacobs EMG; de Graaf AO; Jongen-Lavrencic M; Stevens-Kroef MJPL; Westers TM; Jansen JH
Leukemia; 2024 Apr; 38(4):840-850. PubMed ID: 38297135
[TBL] [Abstract] [Full Text] [Related]
11. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A; Vannucchi AM; Barbui T
Am J Hematol; 2024 Apr; 99(4):697-718. PubMed ID: 38269572
[TBL] [Abstract] [Full Text] [Related]
12. IMMUNOPHENOTYPE OF LEUKEMIC CELLS IN CHRONIC LYMPHOCYTIC leukemia PATIENTS WITH NOTCH1 AND sf3b1 GENE MUTATIONS.
Golyarnik N; Абраменко І; Movchan G; Martina Z; Dyagil I; Chumak A; Bazyka D
Exp Oncol; 2023 Dec; 45(3):322-327. PubMed ID: 38186023
[TBL] [Abstract] [Full Text] [Related]
13. Chronic Lymphocytic leukemia IGHV Somatic Hypermutation Detection by Targeted Capture Next-Generation Sequencing.
Grants JM; May C; Bridgers J; Huang S; Gillis S; Meissner B; Boyle M; Ben-Neriah S; Hung S; Duns G; Hilton L; Gerrie AS; Marra M; Kridel R; Sabatini PJB; Steidl C; Scott DW; Karsan A
Clin Chem; 2024 Jan; 70(1):273-284. PubMed ID: 38175592
[TBL] [Abstract] [Full Text] [Related]
14. Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML.
Wheeler EC; Martin BJE; Doyle WC; Neaher S; Conway CA; Pitton CN; Gorelov RA; Donahue M; Jann JC; Abdel-Wahab O; Taylor J; Seiler M; Buonamici S; Pikman Y; Garcia JS; Belizaire R; Adelman K; Tothova Z
Sci Transl Med; 2024 Jan; 16(728):eade2774. PubMed ID: 38170787
[TBL] [Abstract] [Full Text] [Related]
15. The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.
Khanna V; Lu R; Kumar J; Molina A; Stehr H; Spiteri E; Spinner M; Silva O; Fernandez-Pol S; Tan B; Greenberg PL
Leuk Res; 2024 Jan; 136():107433. PubMed ID: 38154193
[TBL] [Abstract] [Full Text] [Related]
16. TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q).
Tefferi A; Fleti F; Chan O; Al Ali NH; Al-Kali A; Begna KH; Foran JM; Badar T; Khera N; Shah M; Hiwase D; Padron E; Sallman DA; Pardanani A; Arber DA; Orazi A; Reichard KK; He R; Ketterling RP; Gangat N; Komrokji R
Br J Haematol; 2024 Apr; 204(4):1243-1248. PubMed ID: 38083865
[TBL] [Abstract] [Full Text] [Related]
17. JAK2 R683S Mutation Resulting in Dual Diagnoses of Chronic Eosinophilic leukemia and Myelodysplastic/Myeloproliferative Overlap Syndrome.
Krah NM; Miotke L; Li P; Patel JL; Bowen AR; Pomicter AD; Patel AB
J Natl Compr Canc Netw; 2023 Dec; 21(12):1218-1223. PubMed ID: 38081125
[TBL] [Abstract] [Full Text] [Related]
18. How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome.
Xian RR
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):51-58. PubMed ID: 38066895
[TBL] [Abstract] [Full Text] [Related]
19. Next-generation therapy for lower-risk MDS.
Sébert M
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):59-64. PubMed ID: 38066862
[TBL] [Abstract] [Full Text] [Related]
20. Integrative NGS testing reveals clonal dynamics of adverse genomic defects contributing to a natural progression in treatment-naïve CLL patients.
Navrkalova V; Plevova K; Radova L; Porc J; Pal K; Malcikova J; Pavlova S; Doubek M; Panovska A; Kotaskova J; Pospisilova S
Br J Haematol; 2024 Jan; 204(1):240-249. PubMed ID: 38062779
[TBL] [Abstract] [Full Text] [Related]
[Next]
